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ABSTRACT
While the ability of APOBEC3G to reduce the replica-
tion of a range of exogenous retroviruses is now well
established, recent evidence has suggested that
APOBEC3G can also inhibit the replication of endo-
genous retrotransposons that bear long terminal
repeats. Here, we extend this earlier work by showing
that two other members of the human APOBEC3 pro-
tein family, APOBEC3B and APOBEC3A, can reduce
retrotransposition by the intracisternal A-particle
(IAP) retrotransposon in human cells by 20-fold
to up to 100-fold, respectively. This compares to
an  4-fold inhibition in IAP retrotransposition
induced by APOBEC3G. While both APOBEC3G and
APOBEC3B specifically interact with the IAP Gag
protein in co-expressing cells, and induce extensive
editing of IAP reverse transcripts, APOBEC3A fails to
package detectably into IAP virus-like particles and
does not edit IAP reverse transcripts. These data,
which identify human APOBEC3A as a highly potent
inhibitor of LTR-retrotransposon function, are the
first to ascribe a biological activity to APOBEC3A.
Moreover, these results argue that APOBEC3A
inhibitsIAPretrotranspositionviaanovelmechanism
that is distinct from, and in this case more effective
than, the DNA editing mechanism characteristic of
APOBEC3G and APOBEC3B.
INTRODUCTION
The ability of members of the APOBEC3 protein family to
confer intrinsic immunity to retroviral infection was ﬁrst
recognized in the case of APOBEC3G (hA3G), which can
block the replication of human immunodeﬁciency virus
type 1 (HIV-1) mutants lacking a functional copy of the vif
gene (DVif) (1). Subsequently, APOBEC3F (hA3F) was found
to also inhibit the replication of DVif, but not wild-type, HIV-1
variants (2–4). In contrast, APOBEC3B (hA3B) appears able
to inhibit the replication of both wild-type and DVif HIV-1
(5,6). Two other human APOBEC3 proteins, APOBEC3C
(hA3C) and APOBEC3A (hA3A), at most weakly inhibit
either wild-type or DVif HIV-1 (2,5,7,8), although hA3C
has been reported to block the replication of DVif, but not
wild-type, forms of simian immunodeﬁciency virus (SIV) (9).
Inhibitory APOBEC3 proteins speciﬁcally interact with
the nucleocapsid domain of the HIV-1 Gag protein and are
packaged into progeny virions (10–16). During the subsequent
infection of new target cells, the APOBEC3 proteins can
interfere with reverse transcription by inducing extensive
dC to dU editing of nascent proviral minus strands (15–19).
This can induce degradation of the proviral intermediate, per-
haps due to abortive efforts at DNA repair by cellular proteins,
or can lead to fatal mutagenesis. While editing of the retroviral
provirus is therefore a general characteristic of inhibitory
APOBEC3 proteins, it has recently been reported that
some hA3G mutants that are unable to edit can still inhibit
HIV-1DVif replication (20).
While APOBEC3 proteins were ﬁrst identiﬁed as inhibitors
of HIV-1DVif replication, several human APOBEC3 proteins
can also inhibit other retroviruses, including not only SIV
(15,21) but also murine leukemia virus (MLV) (16,19) and
primate foamy virus (PFV) (22,23). Moreover, APOBEC3
proteins have also been shown to act as inhibitors of LTR-
retrotransposon function. Thus, hA3G, hA3F and hA3C can
inhibit Ty1 retrotransposition in yeast cells by up to 100-fold,
and this inhibition correlates with C to T hypermutation of the
Ty1 genome (24,25). In the case of the murine LTR-
retrotransposons intracisternal A-particle (IAP) and MusD,
hA3G was found to reduce retrotransposition in HeLa cells
by  4-fold in the case of IAP and  10-fold in the case of
MusD (26). In both cases, this inhibition again correlated with
C to T hypermutation.
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doi:10.1093/nar/gkj416In this manuscript, we have conﬁrmed the ability of hA3G
to modestly inhibit IAP retrotransposition and demonstrate
that hA3B and hA3A are much more potent inhibitors, reduc-
ing productive IAP retrotransposition by up to 100-fold. Both
hA3G and hA3B induce C to T hypermutation of the IAP
genome and speciﬁcally interact with IAP Gag. In contrast,
hA3A failed to detectably interact with IAP Gag in vivo and
did not induce IAP hypermutation. These data are the ﬁrst to
ascribe a biological activity to hA3A and suggest that hA3A
may have evolvedanovel mechanism toblockretrotransposon
function.
MATERIALS AND METHODS
Molecular clones
We have previously described expression plasmids, based on
pcDNA3, that express C-terminally HA-tagged versions of
hA3A, hA3B, hA3C, hA3F, hA3G and b-arrestin (2,6,21).
Because pcDNA3 contains the neo gene, the APOBEC3 and
b-arrestin open reading frames were excised using HindIII and
XhoI and cloned into the pK expression plasmid (27). The IAP
retrotransposition indicator plasmid pDJ33/440N1neo
TNF has
been previously described (28), as has the pHIV-Luc-DVif
HIV-1 proviral indicator plasmid (2,21).
Retrotransposition and toxicity assays
HeLa cells (3 · 10
5) were co-transfected with 2 mgo fa n
APOBEC3 expression plasmid, or the parental pK vector
as a control, together with 2 mg of pDJ33/440N1neo
TNF,
pcDNA3 or a derivative of pDJ333/440N1neo
TNF lacking a
functional IAP pol gene (28). Forty-eight hours post-
transfection, the transfected cells were harvested and 10
6
plated onto 10 cm dishes. A further 24 h later, the cells
were subjected to selection using G418 (700 mg/ml) and main-
tained in G418 for a further 14 days. At this point, the cultures
were either ﬁxed and stained with crystal violet, and G418
resistant colonies counted, or the cells were used for DNA
isolation using a DNAeasy kit (Qiagen). The entire IAP Gag
openreading framewasthenampliﬁed byPCRandclonedinto
pcDNA3 prior to DNA sequencing.
Inhibition of HIV-1DVif infectivity by different APOBEC3
proteins was assayed as previously described by co-
transfection into 293T cells (2,6,21). Progeny virions were
harvested 48 h after co-transfection and used to infect
CD4
+ CCR5
+ cells. Virus encoded ﬁreﬂy luciferase activity
was then quantitated 24 h post-infection.
Sucrose gradient centrifugation and
protein interaction assays
293T cells (2 · 10
6) were co-transfected with 20 mg of pDJ33/
440N1neo
TNF, or a control plasmid, together with 500 ng of
pK, pK/hA3G or pK/hA3A. At 48 h post-transfection, cells
were harvested into 1 ml of lysis buffer [50 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 0.5% NP-40 and protease inhibitors
(Roche)] and clariﬁed by brief centrifugation. Lysates
obtained from three plates were then pooled and layered
onto a 9 ml 10–80% sucrose gradient. The gradients were
subjected to centrifugation at 40000 r.p.m. for 2 h in an
SW41 rotor. One ml fractions were collected and analyzed
by western blot using either a 1:5000 dilution of a mouse
anti-HA monoclonal (Covance) or a 1:2000 dilution of a rab-
bit anti-IAP Gag polyclonal antiserum (29). Blots were then
treated with horseradish peroxidase-conjugated secondary
antibodies (Amersham) and reactive proteins detected using
chemiluminescence (Lumi-light, Roche). In parallel, cleared
cell lysates obtained from transfected 293T cells were
also used for analysis of in vivo protein binding by co-
immunoprecipitation. ‘Input’ samples were derived directly
from the cell lysates while ‘bound’ samples were obtained
by incubating lysates in the presence of the rabbit polyclonal
anti-IAP Gag antiserum and protein A Agarose (Invitrogen)
for 2 h at 4 C. Western blots were performed as described
above.
The  73 kDa IAP Gag protein was expressed using an
in vitro transcription/translation system and full-length protein
isolated by elution after gel electrophoresis (29). The HA-
tagged hA3A, hA3B and hA3G proteins were expressed by
transfection of the relevant expression plasmids into 293T
cells. At 48 h post-transfection, the cells were lysed in lysis
buffer, clariﬁed and recombinant IAP Gag protein (2 mg total)
added. The lysate was then incubated at 4 C for 4 h, at which
point the rabbit polyclonal anti-IAP Gag antiserum and protein
A Agarose were added. After a further 30 min incubation at
4 C, the bound complexes were collected by centrifugation,
washed and analyzed by western blot.
RESULTS AND DISCUSSION
To examine the ability of human APOBEC3 proteins to inhibit
retrotransposition of IAP in human cells, we co-transfected
HeLa cells with expression plasmids encoding various APO-
BEC3 proteins and the previously described IAP retrotrans-
position indicator construct pDJ33/440N1neo
TNF. This
construct contains a full-length IAP genome with the neo
gene inserted in the antisense orientation (28). The neo
gene is expressed under the control of an SV40 promoter
and is disrupted by an intron in the sense orientation. There-
fore, neo expression requires transcription and splicing of the
IAP transcript, followed by reverse transcription and retro-
transposition into the host cell genome.
As summarized in Figure 1, and demonstrated in
Figure 2A, hA3G expression indeed reduced IAP retro-
transposition by  4-fold, as previously reported by Esnault
et al. (26). Similarly, both hA3C and hA3F reduced IAP
retrotransposition by 2- to 3-fold. In contrast, hA3B reduced
IAP retrotransposition by  20-fold while hA3A reduced IAP
retrotranspositionby50-to100-fold(Figures1and2A).These
differences were not due to major discrepancies in the level of
expression of each APOBEC3 protein in transfected cells
(Figure 1). Moreover, this inhibition did not result from
non-speciﬁc toxicity, as none of the APOBEC3 proteins
had any effect on the number of G418 resistant colonies
obtained upon simple co-transfection of HeLa cells with a
neo expression plasmid (Figure 2B).
It is interesting to compare the effect of human APOBEC3
proteins on IAP retrotransposition with their effect on HIV-1
infectivity. As shown in Figure 1, and previously reported
(1–6,21), hA3G, hA3F and hA3B can potently inhibit the
infectivity of HIV-1DVif virions produced in their presence.
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HIV-1DVif infectivity while hA3A has no detectable pheno-
type. These data demonstrate that there is no correlation
between the effect of human APOBEC3 proteins on IAP retro-
transposition and on HIV-1DVif infectivity and again argue
against any non-speciﬁc toxicity induced by hA3A.
We next used PCR to clone IAP genomic sequences from
the G418 resistant colonies that arose in the HeLa cultures
co-transfected with the IAP indicator plasmid and expression
vectors encoding hA3A,hA3B,hA3Gorb-arrestin,whichwas
used as a control (Figure 2A). No C to T mutations were noted
upon sequencing 4320 bp of the IAP genome sequences
derived from control cultures (data not shown). In contrast,
we detected 79 C to T mutations after sequencing 4550 bp of
IAP sequence obtained from the hA3G co-expressing cultures
(Table 1) and 186 C to T changes after sequencing 5800 bp of
IAP sequence obtained from the hA3B co-expressing cultures
(Table 1). The  2-fold higher level of C to T mutations
detected in the hA3B expressing cultures, when compared
with the hA3G expressing cultures, may correlate with the
 5-fold more severe inhibition of IAP retrotransposition
induced by hA3B when compared with hA3G (Figures 1
and 2A).
Analysis of the sequence context of these C to T mutations
showed that 73 (92%) of the 79 mutations induced by
hA3G were in the sequence context CC* (where the asterisk
indicates the edited residue) while the other 6 (8%) were in
the sequence context TC*. In the case of hA3B, 166 (89%)
of the 186 C to T mutations were in the sequence context TC*,
16 (9%) in the sequence context CC* and 2 each (1%) in the
context AC* or GC*. This sequence preference for editing
of IAP reverse transcripts closely mirrors the hA3G and
hA3B sequence preference previously observed using
HIV-1 (2,3,5,6,17,19).
Surprisingly, sequencing of 22200 bp of IAP sequence
derived from G418 resistant colonies obtained from the cul-
tures co-transfected with the IAP retrotransposition indicator
construct and the hA3A expression plasmid revealed only
background levels of mutagenesis, i.e. we did not observe
signiﬁcant levels of C to T editing (Table 1). This result
therefore strongly suggests that the potent inhibition of IAP
retrotransposition induced by hA3A (Figures 1 and 2A) is not
due to editing of nascent IAP reverse transcripts.
The APOBEC3 protein family, as well as its more distant
relatives APOBEC1, APOBEC2 and AID, contain either one
or two copies of a cytidine deaminase active site, with the
consensus sequence His-X-Glu-X23-28-Pro-Cys-X2-4-Cys, that
also functions as a zinc coordinating region (30). Mutational
disruption of either of the two active sites in hA3G can inhibit
the ability ofhA3Gtoblock HIV-1replication(16). Moreover,
we have previously shown that mutation of active site residues
95-SPC-97 or 286-SPC-288 of hA3G to alanine disrupts the
ability of hA3G to inhibit retrotransposition by Ty1 in yeast
cells (24). We therefore introduced this same inactivating
mutant into the same three active site residues in hA3A
(99-SPC-101 to AAA) and asked whether this would affect
theabilityofhA3AtoinhibitIAP retrotransposition. Asshown
in Figure 3, the hA3A (SPC-AAA) mutant was expressed at a
level that was comparable with wild-type hA3A in transfected
cells and, more importantly, fully retained its ability to block
IAP retrotransposition. These data are therefore fully consis-
tent with the hypothesis that disruption of IAP retrotranspo-
sition by hA3A occurs independently of editing.
Inhibition of retrovirus replication, and of Ty1 retrotrans-
position, by speciﬁc APOBEC3 proteins is mediated by their
selective incorporation into retroviral or retrotransposon par-
ticles due to a speciﬁc interaction with the Gag protein (6,10–
14,22,24,31). We therefore used co-immunoprecipitation to
ask whether hA3A, hA3B and hA3G also speciﬁcally interact
with the IAP Gag protein in vivo. In this experiment, 293T
cells were co-transfected with an expression vector expressing
an HA-tagged APOBEC3 or control protein (b-arrestin),
together with an IAP Gag expression plasmid (28). Proteins
bound to IAP Gag in vivo were collected by immunoprecipi-
tation at 48 h after transfection using an IAP Gag-speciﬁc
antiserum (29). As shown in Figure 4A, we observed a readily
detectable interaction between either hA3B or hA3G and IAP
Gag. In contrast, we did not observe co-immunoprecipitation
of IAP Gag with hA3A or b-arrestin, a human cytoplasmic
protein used as a negative control, in several independent
experiments.
While the experiment shown in Figure 4A looked at the
ability of hA3A, hA3B and hA3G to interact with the IAP Gag
protein in vivo, we also wished to test whether these proteins
could interact in vitro. For this purpose, we prepared full-
length, recombinant IAP Gag (29) and then added this puriﬁed
protein to cell lysates prepared from 293T cells transfected
Figure 1. Effect of human APOBEC3 proteins on IAP retrotransposition
and HIV-1 infectivity. Upper panel: IAP retrotransposition was quantified
by co-transfection of HeLa cells with the IAP retrotransposition indicator
construct pDJ33/440N1neo
TNF and the indicated APOBEC3 expression plas-
mids. After selection in G418, resistant colonies were counted. The effect of
the same APOBEC3 proteins on HIV-1DVif infectivity was determined by
co-transfection into 293T cells together with the pHIV-Luc-DVif indicator
construct. Released HIV-1 virions were collected at 48 h and used to infect
CD4
+, CCR5
+ cells. Induced, virus encoded luciferase activity was quantified
24 h later. In both cases, data are presented as a percentage of the activity seen
in cultures co-transfected with a plasmid expressing the irrelevant b-arrestin
gene. Average of three independent experiments with standard deviation
indicated. Lower panel: western analysis of APOBEC3 protein expression
in transfected 293T cells using an anti-HA tag specific mouse monoclonal.
hA3A and hA3C are predicted to be  22 kDa in size while hA3B, hA3F and
hA3G are  40 kDa.
Nucleic Acids Research, 2006, Vol. 34, No. 1 91with plasmids expressing hA3A, hA3B, hA3G or b-arrestin.
Protein complexes containing IAP Gag were then collected
and analyzed by western blot. As shown in Figure 4B, we
again observed a readily detectable interaction between
hA3B or hA3G and IAP Gag. Remarkably, however, we
also consistently observed speciﬁc binding of hA3A, but
not of the b-arrestin control protein, by IAP Gag in this
in vitro assay. No binding to the protein A Sepharose matrix
was observed if the recombinant IAP Gag protein was omitted
from the reaction (data not shown). Therefore, it appears that
hA3A, hA3B and hA3G can all interact with IAP Gag in vitro
(Figure 4B) but that hA3A differs from hA3B and hA3G in
being unable to form a stable complex with IAP Gag in vivo
(Figure 4A).
In yeast cells expressing hA3G, the hA3G protein migrates
at its predicted, <100 kDa size on sucrose gradients in the
absence of Ty1 Gag but moves to high molecular mass
(HMM) fractions when Ty1 Gag is co-expressed (24). Pre-
sumably, this reﬂects incorporation of hA3G into Ty1
retrovirus-like particles. We therefore asked whether the
migration of hA3A or hA3G on a similar sucrose gradient
would be affected by co-expression of IAP Gag, and vice
versa. As shown in Figure 5, all of the IAP Gag protein
migrated to near the bottom of the sucrose gradient, consistent
Figure2.EffectofAPOBEC3proteinsonIAPretrotranspositionandcellviability.(A)HeLacellsweretransfectedwiththeIAPretrotranspositionindicatorplasmid
pDJ33/440N1neo
TNF, together with an APOBEC3 expression plasmid or a control plasmid expressing b-arrestin. A derivative of pDJ33/440N1neo
TNF lacking a
functionalpolgeneservedasthenegativecontrol.CellsweresubjectedtoselectioninG418andresistantcoloniescounted17daysaftertransfection.Thisexperiment
is representative ofthedatacompiledin Figure1. (B)Sameas(A) exceptthatHeLacells wereco-transfectedwithpcDNA3,whichencodesa neocDNA,insteadof
with pDJ33/440N1neo
TNF. The negative in this case is a mock transfection.
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(29), and this migration was unaffected by hA3G or hA3A
co-expression. Analysis of the hA3A protein showed that
hA3A resided almost exclusively near the top of the sucrose
gradient, well away from the HMM fractions containing the
IAP Gag protein, regardless of whether IAP Gag was co-
expressed or not (Figure 5). This result is consistent with
our inability to detect an in vivo IAP Gag:hA3A interaction
by co-immunoprecipitation (Figure 4A).
In contrast to hA3A, hA3G was found to migrate into the
HMM segment of the sucrose gradient and was, in fact, found
in almost exactly the same fractions as the IAP Gag protein
(Figure 5). Remarkably, the mobility of hA3G on this sucrose
gradient was not affected by IAP Gag co-expression, i.e. it
migrated at an HMM regardless of whether IAP Gag was
co-expressed (Figure 5).
It isinteresting tocontrast this result, obtainedin 293T cells,
with the situation in yeast, where hA3G migrated with an
HMM in the presence of Ty1 Gag but at a low molecular
mass in its absence (24). These yeast data argue that hA3G,
which is clearly active in yeast cells (24,25), is only recruited
into an HMM complex, at least in yeast cells, when a target
Gag protein is co-expressed. Yet, in transfected 293T cells,
hA3G is in an HMM complex even in the absence of IAP Gag
co-expression (Figure 5).Thisresultconﬁrms therecentobser-
vation by Chiu et al. (32) that hA3G is found in a large,
>700 kDa protein complex in actively growing human cell
lines, although hA3G did migrate closer to its predicted
molecular mass in resting primary human T-cells and mono-
cytes. Chiu et al. (32) proposed, based on these data, that
hA3G was incorporated into an HMM complex in dividing
cells that perhaps functions to block inappropriate editing of
cellular DNA by hA3G during host cell DNA synthesis.
Based on the data presented in Figure 5, and previously
obtained in yeast cells (24), we propose that the HMM com-
plex containing hA3G actually results from incorporation of
hA3G into retrovirus-like particles derived from endogenous
retroviruses and retrotransposons. Human cells contain  230
000 endogenous retroviruses (26) and many of these are tran-
scriptionally active, especially in dividing cells (33–37). We
know that hA3G isable to interact with a wide range of diverse
retroviral and retrotransposon Gag proteins, including HIV-1,
MLV, PFV, Ty1 and IAP Gag (10–14,22,24,31) (Figure 2); so
Table 1. Relative levels of C to T editing induced in retrotransposed IAP
genome sequences by co-expressed APOBEC3 proteins
hA3A
(22200)
A T C G hA3B
(5800)
A T C G hA3G
(4550)
AT C G
A– 1 0 0 A – 0 0 2 A – 0 0 0
T0 – 4 0 T 0 – 2 0 T 0 – 0 0
C 0 3 – 0 C 0 186 – 0 C 1 79 – 0
G0 0 0 – G 1 0 0 – G 0 0 0 –
G418 resistant colonies obtained upon co-transfection of HeLa cells with the
pDJ33/440N1neo
TNF IAP indicator construct, and plasmids expressing hA3A,
hA3B or hA3G, were harvested and used to prepare DNA. IAP genomic
sequences were then PCR amplified, cloned and sequenced. The total number
ofbasessequencedisshowninparentheses,withmutationsindicatedinthegrid.
Predicted bases are shown on the left and the observed bases across the top.
Figure 3. An hA3A mutant bearing a defective cytidine deaminase active site
remains able to inhibitIAP retrotransposition. These data were derived and are
presented as described in Figure 1 and again used a primary antibody specific
fortheHA epitopetag,presentonboththeb-arrestinandhA3Aproteins,inthe
lower panel. The hA3A (SPC-AAA) mutant bears alanine residues in place of
the active site residues 99-SPC-101.
Figure 4. Binding of IAP Gag by APOBEC3 proteins in vivo and in vitro.
(A) 293T cells were co-transfected with the IAP Gag expression plasmid
pDJ33/440N1neo
TNF and vectors expressing HA-tagged hA3A, hA3B,
hA3G or b-arrestin, the latter as a negative control. After 48 h, the cells were
lysed and an aliquot retained to analyze input protein levels. The remaining
lysate was incubated with a rabbit anti-IAP Gag antiserum and protein A
agarose.Bound,aswellasinput,proteinswereseparatedbygelelectrophoresis
and visualized by western blot using a mouse monoclonal specific for the
HA tag present on the APOBEC3 and b-arrestin proteins, or using the anti-
IAP Gag antiserum. (B) 293T cells were transfected with plasmids expressing
HA-tagged hA3A,hA3B,hA3Gorb-arrestinandlysatesprepared2days later.
After incubation in the presence of purified full-length recombinant IAP Gag,
Gag protein complexes were collected using a rabbit polyclonal anti-Gag anti-
serumandproteinAagarose.Boundandinputproteinswerethenvisualizedby
westernblotusingananti-HAmonoclonal.Forbothpanels,inputlanescontain
2% of the starting material while bound lanes contain 25% of the immunopre-
cipitated protein fraction.
Nucleic Acids Research, 2006, Vol. 34, No. 1 93it seems likely that hA3G would also interact with many
endogenous retroviral Gag proteins. Of note, Chiu et al.
(32) showed that the HMM complex containing hA3G is dis-
rupted by RNase treatment. This is striking, as RNase also
disrupts the ability of hA3G to interact with HIV-1 Gag, MLV
Gag and Ty1 Gag (10,12,14,24,31,38). We therefore hypothe-
size that the HMM complex formed by hA3G in actively
replicating human cells results from the formation of a het-
erogeneous mixture of endogenous retrovirus Gag:hA3G com-
plexes that, in cells co-expressing hA3G and IAP Gag, also
include IAP Gag:hA3G complexes (Figure 3).
The most surprising result reported in this manuscript is that
hA3A is an extremely potent inhibitor of IAP retrotransposi-
tion (Figures 1 and 2A). Remarkably, hA3A has not been
previously observed to signiﬁcantly inhibit the infectivity of
any retrovirus tested (2,5,7,22,31); so this result represents the
ﬁrst report of a biological activity for hA3A. While hA3A is
actually a more potent inhibitor of IAP retrotransposition than
either hA3B or hA3G, hA3A differs from both these proteins
in that it neither induced C to T hypermutation of the IAP
genome (Table 1) nor detectably interacted with Gag in co-
expressing cells (Figures 4A and 5). We therefore do not
understand the molecular basis for this inhibition, although
we do know that hA3A is not a non-speciﬁc inhibitor of HeLa
transformation to G418 resistance (Figure 2B) and does not
signiﬁcantly affect IAP Gag expression in co-transfected cells
(Figure 5). Of note, a previously described (24) inactivating
mutation of the cytidine deaminase active sites in hA3G did
not block the ability of hA3A to inhibit IAP retrotransposition
when introduced into hA3A (99-SPC-101!AAA) (Figure 3),
aresultwhich isfullyconsistentwiththelackofanydetectable
editing of the IAP genome by wild-type hA3A.
While hA3A failed to detectably interact with IAP Gag
in vivo (Figures 4A and 5), we did observe a speciﬁc inter-
action between hA3A and recombinant IAP Gag protein
in vitro (Figure 4B). This result raises the intriguing possibility
that hA3A may transiently interact with IAP retrovirus-like
particles either during their assembly or during the disas-
sembly that is predicted to occur prior to the chromosomal
integration of full-length IAP reverse transcripts. Unfortu-
nately, we have not been able to quantify the level of IAP
reverse transcripts in transfected cells in the absence of selec-
tion (data not shown) so we do not know whether hA3A acts
before or after IAP reverse transcription. In any event, we can
only hypothesize that hA3A utilizes a novel mechanism for
inhibition of IAP retrotransposition that does not involve DNA
editing. In this context, we note that Newman et al. (20) have
proposed that inhibition of HIV-1 replication by hA3G can
still be observed with certain hA3G mutants that lack a func-
tional cytidine deaminase active site. Moreover, inhibition of
Hepatitis B virus replication by hA3G may occur in the
absence of signiﬁcant editing (39,40), although this issue
remains controversial (41). Whether this currently undeﬁned
second inhibitory mechanism is also used by hA3A to inhibit
IAP retrotransposition is not currently known.
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